Inhibitex Inc (NASDAQ:INHX) to Hold Q2 2008 Earnings Conference Call August 12

Inhibitex, Inc (NASDAQ:INHX) will hold a conference call on Tuesday, August 12 at 8:30 am ET to discuss the financial results.  Interested parties may listen to the presentation by dialing 888-680-0878 or 617-213-4855 for international callers.  The access code for the call is 29157221.

Inhibitex, Inc. is a biopharmaceutical company focused on the development of differentiated anti-infective products. It pursues pre-clinical or clinical-stage antiviral development programs via in-licensing or acquisition.

On September 19, 2007, the Company completed the acquisition of FermaVir Pharmaceuticals, Inc. (FermaVir). FermaVir’s development-stage antiviral pipeline included FV-100, a nucleoside analogue for the treatment of herpes zoster infections (shingles), and a series of preclinical nucleoside analogue compounds for the treatment of human cytomegalovirus (CMV) disease.

On September 11, 2007, the Company entered into a license agreement to cover a series of human immunodeficiency virus (HIV) integrase inhibitors and other antiviral compounds. On November 19, 2007, the Company entered into a license agreement for covering a series of hepatitis C virus (HCV) polymerase inhibitors.

Read more Business News on The Global Market Directory.

About The Global Market Directory (TheGMD)

TheGMD provides an online global directory listing featuring public companies, stock brokers, brokerage firms and individuals.  The GMD provides profiles for Brokerage Firms, Stock Brokers and Individuals in addition to Public Companies.

The GMD is a division of TransWorldNews, Inc. Companies can utilize the TransWorldNews press release distribution services and have all news releases attached to their GMD profile.

Create your profile on The Global Market Directory.